AURIMOD logo

AURIMOD

AURIMOD develops VIVO, a chronic pain wearable using auricular vagus nerve stimulation.

ShareLink copied

The record

Vertical
Devices & Robotics
Sub-segment
Chronic pain neuromodulation
Product type
Device
Headquarters
Vienna, Austria
Region
Europe

What they do

Vienna-based AURIMOD is led by founder and CEO Stefan Kampusch, identified by KPMG. Its official site describes VIVO as a Class IIa medical device using auricular vagus nerve stimulation, or aVNS, for chronic pain. VIVO Pal is its accompanying digital pain diary app.

History and progression

How AURIMOD got here, step by step.

  1. 11 November 2026

    KPMG Global Tech Innovator winner

    AURIMOD won the KPMG Private Enterprise Global Tech Innovator 2026 global final in Lisbon. TissueLabs placed second.

    Source

Sources

  1. KPMG winner announcement
  2. KPMG global final report
  3. The HealthTech Signal: Web Summit Lisbon 2026 preview

Related companies

Is this your company? Feature it